Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women With Type 2 Diabetes.

  title={Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women With Type 2 Diabetes.},
  author={Jennifer W. Wu and Laurent Azoulay and Agnieszka Majdan and Jean-François Boivin and Michael N. Pollak and Samy Suissa},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  volume={35 32},
  • Jennifer W. WuL. Azoulay S. Suissa
  • Published 27 September 2017
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Purpose The association between long-acting insulin analogs and increased breast cancer risk is uncertain, particularly with the short follow-up in previous studies. [] Key Method Methods A population-based cohort of women 40 years or older, all of whom were treated with long-acting (glargine, detemir) or neutral protamine Hagedorn (NPH) insulin between 2002 and 2012, was formed using the United Kingdom's Clinical Practice Research Datalink. Women were followed until February 2015 or breast cancer diagnosis…

Figures and Tables from this paper

Long-term use of basal insulin and the risk of breast cancer

The primary care data do not support the findings of Wu et al. regarding the relative risk of breast cancer in women treated with insulin glargine compared with those receiving NPH, and argues against the likelihood of a true increase in breast cancer risk with gl argine use.

A Prospective Study of Type 2 diabetes, metformin use, and risk of breast cancer.

Association of antidiabetic medication and statins with breast cancer incidence in women with type 2 diabetes

No evidence of an association between the use of metformin or statins and the incidence of breast cancer in women with T2D was found, but among insulin users, a slightly higher incidence of Breast cancer was observed.

Type 2 Diabetes, but Not Insulin (Analog) Treatment, Is Associated With More Advanced Stages of Breast Cancer: A National Linkage of Cancer and Pharmacy Registries

It is suggested that women with T2D are at increased risk to be diagnosed with a more aggressive type of breast cancer than women without diabetes.

Insulin therapy and biliary tract cancer: insights from real-world data

The relationship between insulin therapy and BTC is type-specific and insulin therapy was associated with an increased risk of ECC, and no statistically significant results were observed for insulin and ICC/GBC.

Long-acting insulin analogs and cancer.

A national observation study of cancer incidence and mortality risks in type 2 diabetes compared to the background population over time

Changing patterns in cancer incidence and deaths in diabetes compared to the background population are examined to find that Persons with type 2 diabetes are at greater risk of developing cancer and lower chance of surviving it.

Insulin glargine use and breast cancer: a systematic review and meta-analysis

The results were inconclusive, human studies showed no relation of insulin glargine with breast cancer except at high dose and long duration of ≥ five years, and prior human insulin use, while the experimental studies showed a decreased breast cancer latency.

Does metformin affect mammographic breast density in postmenopausal women with type 2 diabetes

  • M. OzturkS. Ozturk A. Ozdemir
  • Medicine
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • 2020
In conclusion, metformin has no statistically significant effect on MBD in postmenopausal female patients with T2DM.

Effects of insulin and analogues on carcinogen-induced mammary tumours in high-fat-fed rats

In this model of oestrogen-dependent breast cancer in insulin-resistant rats, insulin and insulin analogues increased tumour multiplicity with no difference between insulin types.



Long-term effects of insulin glargine on the risk of breast cancer

The risk of breast cancer in women with type 2 diabetes is not increased during the first 5 years of insulin glargine use, however, longer-term use may increase this risk, particularly in Women with longstanding use of insulin before starting insulinglargine.

Cancer Risk Associated with Insulin Glargine among Adult Type 2 Diabetes Patients – A Nationwide Cohort Study

Insulin glargine use did not increase the risk of overall cancer incidence as compared with intermediate/long-acting human insulin, and the positive associations with pancreatic and prostate cancer need further evaluation and validation.

Effect of Long-Acting Insulin Analogs on the Risk of Cancer: A Systematic Review of Observational Studies

The observational studies examining the risk of cancer associated with long-acting insulin analogs have important methodological shortcomings that limit the conclusions that can be drawn, particularly for breast cancer risk.

Cancer Incidence Among Those Initiating Insulin Therapy With Glargine Versus Human NPH Insulin

Patients initiating insulin glargine rather than NPH do not seem to be at an increased risk for cancer, and this evidence is very limited mainly based on actual dynamics in insulin prescribing.

Risk of Breast Cancer by Individual Insulin Use: An International Multicenter Study

This international study found no difference in the risk of developing breast cancer in patients with diabetes among the different types of insulin with short- to mid-term duration of use.

Cohort Study of Insulin Glargine and Risk of Breast, Prostate, and Colorectal Cancer Among Patients With Diabetes

Results of this study should be viewed cautiously, given the relatively short duration of glargine use to date and the large number of potential associations examined.

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

Those on insulin or insulin secretagogues were more likely to develop solid cancers than those on metformin, and combination with met formin abolished most of this excess risk.

Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study

Users of insulin glargine and users of other insulin analogues had a lower risk of cancer in general than those using human insulin, and an increased risk of breast cancer in users of insulinglargine in comparison with users of human insulin.

Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group

Overall, insulin glargine use was not associated with an increased risk of all cancers or site-specific cancers in Scotland over a 4 year time frame, and the excess of cases of all cancer and breast cancer in the subgroup of insulinglargine only users to more likely reflect allocation bias rather than an effect of insulin gl argine itself.